Neuroplasticity in the use of a human glucone-like peptide-1 analog in an obese patient: clinical case

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This clinical case reflects a variety of symptoms in obesity with central nervous system involvement. At the same time, the use of liraglutide in an obese patient resulted not only in the reduction of visceral fat area, but also in the improvement of cognitive functions, reduction of neuropilin, and as a consequence, reversibility of neurometabolism and functional changes in the brain. Literature sources from international and Russian databases for 5 years were used to compare the results.

全文:

受限制的访问

作者简介

M. Matveeva

Siberian State Medical University, Ministry of Health of Russia

Email: oleynikoa@mail.ru
ORCID iD: 0000-0001-9966-6686

Professor, MD

俄罗斯联邦, Tomsk

Yu. Samoilova

Siberian State Medical University, Ministry of Health of Russia

Email: oleynikoa@mail.ru
ORCID iD: 0000-0002-2667-4842

Professor, MD

俄罗斯联邦, Tomsk

O. Oleynik

Siberian State Medical University, Ministry of Health of Russia

Email: oleynikoa@mail.ru
ORCID iD: 0000-0002-2915-384X

Candidate of Medical Sciences

俄罗斯联邦, Tomsk

D. Kudlay

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; M.V. Lomonosov Moscow State University

Email: oleynikoa@mail.ru
ORCID iD: 0000-0003-1878-4467

Professor, Corresponding member of the Russian Academy of Sciences, MD

俄罗斯联邦, Moscow; Moscow

D. Podchinenova

Siberian State Medical University, Ministry of Health of Russia

编辑信件的主要联系方式.
Email: oleynikoa@mail.ru
ORCID iD: 0000-0001-6212-4568

Candidate of Medical Sciences

俄罗斯联邦, Tomsk

D. Apalkov

Siberian State Medical University, Ministry of Health of Russia

Email: oleynikoa@mail.ru
俄罗斯联邦, Tomsk

参考

  1. Mayoral L.P., Andrade G.M., Mayoral E.P. et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020; 151 (1): 11–21. doi: 10.4103/ijmr.IJMR_1768_17
  2. Hruby A., Hu F.B. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015; 33 (7): 673–89. doi: 10.1007/s40273-014-0243-x
  3. Ortega F.B., Mora-Gonzalez J., Cadenas-Sanchez C. et al. Effects of an Exercise Program on Brain Health Outcomes for Children With Overweight or Obesity: The ActiveBrains Randomized Clinical Trial. JAMA Netw Open. 2022; 5 (8): e2227893. doi: 10.1001/jamanetworkopen.2022.27893
  4. Selman A., Burns S., Reddy A.P. et al. The Role of Obesity and Diabetes in Dementia. Int J Mol Sci. 2022; 23 (16): 9267. doi: 10.3390/ijms23169267
  5. Benomar Y., Taouis M. Molecular Mechanisms Underlying Obesity-Induced Hypothalamic Inflammation and Insulin Resistance: Pivotal Role of Resistin/TLR4 Pathways. Front Endocrinol (Lausanne). 2019; 10: 140. doi: 10.3389/fendo.2019.00140
  6. Flores-Cordero J.A., Pérez-Pérez A., Jiménez-Cortegana C. et al. Obesity as a Risk Factor for Dementia and Alzheimer's Disease: The Role of Leptin. Int J Mol Sci. 2022; 23 (9): 5202. doi: 10.3390/ijms23095202
  7. Cui Q.N., Stein L.M., Fortin S.M. et al. The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma. Br J Pharmacol. 2022; 179 (4): 715–26. doi: 10.1111/bph.15683
  8. Nakanishi Y., Kang S., Kumanogoh A. Axon guidance molecules in immunometabolic diseases. Inflamm Regen. 2022; 42 (1): 5. doi: 10.1186/s41232-021-00189-0
  9. Al-Thomali A.W., Al-Kuraishy H.M., Al-Gareeb A.I. et al. Role of Neuropilin 1 in COVID-19 Patients with Acute Ischemic Stroke. Biomedicines. 2022; 10 (8): 2032. doi: 10.3390/biomedicines10082032
  10. Дедов И.И., Шестакова М.В., Мельниченко Г.А. и др. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний». Ожирение и метаболизм. 2021; 18 (1): 5–99 [Dedov I.I., Shestakova M.V., Melnichenko G.A. et al. Interdisciplinary clinical practice guidelines "Management of obesity and its comorbidities". Obesity and metabolism. 2021; 18 (1): 5–99 (in Russ.)]. doi: 10.14341/omet12714
  11. Caballero B. Humans against Obesity: Who Will Win? Adv Nutr. 2019; 10 (suppl_1): S4–S9. doi: 10.1093/advances/nmy055
  12. Melchior V., Fuchs S., Scantamburlo G. Vignette thérapeutique de l’étudiant. Obésité et troubles du comportement alimentaire [Obesity and eating disorders]. Rev Med Liege. 2021; 76 (2): 134–9 (in French).
  13. Ho Y.C., Srinivasan R.S. Lymphatic Vasculature in Energy Homeostasis and Obesity. Front Physiol. 2020; 11: 3. doi: 10.3389/fphys.2020.00003
  14. Song S., Guo R., Mehmood A. et al. Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway. CNS Neurosci Ther. 2022; 28 (3): 422–34. doi: 10.1111/cns.13791
  15. Drucker D.J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022; 57: 101351. doi: 10.1016/j.molmet.2021.101351
  16. Knudsen L.B., Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019; 10: 155. doi: 10.3389/fendo.2019.00155
  17. Varkevisser R.D.M., van Stralen M.M., Kroeze W. et al. Determinants of weight loss maintenance: a systematic review. Obes Rev. 2019; 20 (2): 171–211. doi: 10.1111/obr.12772
  18. Val-Laillet D., Aarts E., Weber B. et al. Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity. Neuroimage Clin. 2015; 8: 1–31. doi: 10.1016/j.nicl.2015.03.016

补充文件

附件文件
动作
1. JATS XML
下载
2. Changes in the standard deviation score of body mass index from birth to 18 years of age

下载 (18KB)
索引源数据
##common.cookie##